Israel Active

Israel’s DreaMed Diabetes (reported previously) is integrating its Advisor Pro software at Texas Children's Hospital. It allows diabetic children to be monitored remotely and avoids the risk of them (and their parents / guardians) being infected in hospital with Covid-19.

Israel’s VBL Therapeutics (reported previously) has been awarded a grant of up to $0.9 million by the Israel Innovation Authority.  It will support the Phase 3 study of VBL’s lead candidate VB-111 for the treatment of platinum-resistant ovarian cancer.

The Israel Precision Medicine Partnership (IPMP – ), has granted another NIS 60 million to 16 projects researching into specific targeted personalized medicine that can treat ailments such as autism, cancers and trauma.

Israel’s NUVO has partnered with Jerusalem’s Hadassah hospital to develop an AI platform for accurate decision-making about pregnancy complications. NUVO has also just received US FDA approval for its INVU device (reported previously) to be used in monitoring maternal fetal heart rate.

Israel’s Habitu develops a platform specifically targeting clinical trials and patient support programs in community-based healthcare. It provides flexible, continuous, emotional, professional and procedural support to patients, leading to more efficient trials and lower drop-out rates.

Israel’s Endospan (reported previously) has been granted Breakthrough Device Designation from the U.S. FDA for its NEXUS Aortic Arch Stent Graft System.  It already has the CE Mark of European approval.

Israel’s Immunai is developing a technological platform that aims to map the entire immune system for better detection, diagnosis, and treatment of disease. It uses single cell genomics that could in the future unlock the secrets of infections, cancer and autoimmune diseases.

The Israeli Chief Medical Officer of US biotech Moderna reported that company’s mRNA-1273 Covid-19 vaccine successfully produced antibodies on 8 patients. Dr. Tal Zaks received his M.D. and Ph.D. from Ben Gurion University, joining Moderna in 2015.

Seven of the eight critically ill coronavirus patients on ventilators, treated with PLX stem cells from Israel’s Pluristem, survived after 28 days.  Only one of those still needed mechanical ventilation - the other five having been discharged from hospital. 10 further patients have now begun treatment.

The Israel Institute for Biological Research (IIBR) in Ness Ziona has just completed the patent application process for eight new coronavirus antibodies (reported previously).